Education IFCC C-EUBD

The network is supervised by the IFCC Committee on Traceability in Laboratory medicine (C-TLM) and the Committee on Education in the Use of Biomarkers in Diabetes (C-EUBD).

Chair of C-EUBD is Prof. Garry John. (garry.john@nnuh.nhs.uk).

Below are the members of the committee and the terms of reference.

NamePositionCountryTermTime in Office
G. JohnChairUK2nd2019 01 - 2021 12
E. EnglishMemberUK2nd2019 01 - 2021 12
A. SatoMemberJP1st2019 03 - 2021 12
D. SacksMemberUS2nd2019 01 - 2021 12
C. WeykampMemberNL2nd2019 01 - 2021 12
E. Lenters-WestraConssultant NL

Terms of reference

  1. To maintain and further develop the network of reference laboratories for the measurement of HbA1c (through collaboration with C-TLM)
  2. To work in partnership with WHO and IDF to continue to promote the reporting of HbA1c in line with the consensus statement
  3. To work in partnership with WHO and IDF to facilitate the development and implementation of international guidelines for the use of HbA1c in the diagnosis of diabetes
  4. To work with IFCC Corporate Members to develop a consensus position on the information to be included in the Instructions for Use (IFU) as it relates to the clinical use of HbA1c methods
  5. Develop quality targets for the measurement of HbA1c and other biomarkers, and on the basis of these targets, and in conjunction with professional bodies, advise on the use of biomarkers for monitoring, diagnosis and screening of diabetes and glucose intolerance.
  6. To work with WHO and TF-POCT to recommend best practice in the use of POCT methods for the measurement of HbA1c
  7. To evaluate the clinical value of emerging biomarkers (e.g. glycated albumin) for the management of patients with diabetes and to establish whether there is a case for method harmonisation of effective new biomarkers
  8. To evaluate the emerging importance of post translational modification derived products (PTMDPs), and especially Advanced Glycation End-Products (AGEs), and work with Professional bodies on the best way of developing these for use in diabetes.
  9. To monitor the literature and advise on best practice in relation to laboratory aspects of diabetes.